• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

    5/8/25 5:00:00 AM ET
    $COYA
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $COYA alert in real time by email

    Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of challenging therapeutic areas.  

    "Having an industry leader of Dieter's stature head our Board underscores the potential of Sibylla's technology to reshape the drug discovery landscape by unlocking access to a range of previously undruggable targets. Dieter's demonstrated success in driving value from R&D to the commercialization of impactful medicines will guide the next stages of Sibylla's growth as we advance our pipeline of folding interference small molecules in preclinical studies. Personally, I will be honored to have him at our side," said Lidia Pieri, PhD, MBA, Co-Founder and Chief Executive Officer of Sibylla Biotech.

    "Sibylla's unique approach to targeting protein degradation during the folding process has the opportunity to revolutionize this field and open new avenues for recognized but currently inaccessible targets across high-need diseases. The company has made strides in growing the organization, progressing its technology and securing strategic drug discovery collaborations. I look forward to working with the team to reach new corporate and clinical milestones," added Dieter Weinand, Chairman of the Board of Sibylla Biotech.

    With a career marked by significant achievements across pharmaceutical development, commercialization and global leadership, Mr. Weinand has established himself as a prominent industry veteran. He most recently led the Global Primary Care Business at Sanofi, where he optimized the company's portfolios. As President, CEO and Chairman of the Board at Bayer Pharmaceuticals AG, Mr. Weinand oversaw the integration of R&D, manufacturing, and all commercial and support functions for the healthcare division, thereby executing critical growth strategies. Mr. Weinand has held significant senior management roles at Bristol-Meyers Squibb, Pfizer and other leading big pharma companies. His contributions have been essential to the launch of several high-impact medicines, including Lipitor®, Neurontin®, Abilify® and Cipro®.

    Mr. Weinand holds a B.A. in Biology from Concordia College, New York, and an M.S. in Pharmacology and Toxicology from Long Island University, New York. He serves as Chairman of the Board at companies including Confo Therapeutics, DISCO Pharmaceuticals and FORE Biotherapeutics. In addition, he is the Lead Independent Director at Replimune (NASDAQ:REPL) and a Board Member at Coya Therapeutics (NASDAQ:COYA).

    About Sibylla Biotech

    Sibylla is transforming drug discovery by targeting protein folding intermediates, a new druggable dimension in the pharmacological space. Unlike most drugs that act on native proteins, we intervene earlier-targeting proteins before they become undruggable.

    Thanks to our proprietary technology platform, PPI-FIT, we can predict and target intermediate steps in the protein folding process.

    Our small molecule drugs interfere with the folding process, leading to targeted protein degradation through the physiological pathway.

    Sibylla is building an exciting pipeline of treatments for diseases with high medical need across multiple therapeutic areas, with the mission to bring protein folding interference therapeutics to patients.

    For further information: https://www.sibyllabiotech.it/

    Sibylla Biotech Contact

    Lidia Pieri

    +39 347 6499534

    [email protected]

    Sibylla Biotech Media Contact

    Trophic Communications

    Valeria Fisher

    +49 175 80 41 816

    [email protected]

    Attachments

    • 20250508_Sibylla_DW Chairman_EN
    • Headshot of Dieter Weinand


    Primary Logo

    Get the next $COYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COYA
    $REPL

    CompanyDatePrice TargetRatingAnalyst
    Coya Therapeutics Inc.
    $COYA
    12/4/2024$15.00Buy
    D. Boral Capital
    Replimune Group Inc.
    $REPL
    8/28/2024$17.00Buy
    ROTH MKM
    Replimune Group Inc.
    $REPL
    4/17/2023$44.00Overweight
    Piper Sandler
    Replimune Group Inc.
    $REPL
    11/19/2021$52.00Overweight
    Piper Sandler
    Replimune Group Inc.
    $REPL
    10/15/2021$60.00Buy
    BTIG Research
    Replimune Group Inc.
    $REPL
    8/23/2021$55.00 → $49.00Outperform
    SVB Leerink
    Replimune Group Inc.
    $REPL
    8/9/2021$56.00 → $55.00Outperform
    SVB Leerink
    More analyst ratings

    $COYA
    $REPL
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by Coya Therapeutics Inc.

      10-K/A - Coya Therapeutics, Inc. (0001835022) (Filer)

      4/28/25 5:07:30 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Replimune Group Inc.

      S-8 - Replimune Group, Inc. (0001737953) (Filer)

      4/25/25 5:24:57 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Coya Therapeutics Inc.

      10-K - Coya Therapeutics, Inc. (0001835022) (Filer)

      3/18/25 8:26:15 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $COYA
    $REPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 18 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 21,960 shares of the Company's common stock and restricted stock units representing an aggregate of 44,005 sh

      5/9/25 4:01:00 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in two upcoming conferences in May 2025. Chief Executive Officer Arun Swaminathan, Ph.D. and Chief Financial Officer David Snyder will be available for one-on-one meetings with registered investors of the following conferences: Event: D. Boral Capital Inaugural Global Conference Date: May 14, 2025 Registration: Contact John Perez at [email protected] Location: The Plaza Hotel 768 Fifth Avenue New York, NY 10019   Event:

      5/8/25 8:15:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $COYA
    $REPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Peeples-Dyer Veleka

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      4/3/25 8:06:46 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Patel Sushil was granted 166,667 shares, increasing direct ownership by 83% to 368,681 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      4/3/25 8:06:13 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Pucci Paolo

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      4/3/25 8:05:36 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $COYA
    $REPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Coya Therapeutics with a new price target

      D. Boral Capital initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $15.00

      12/4/24 7:30:44 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Replimune with a new price target

      ROTH MKM initiated coverage of Replimune with a rating of Buy and set a new price target of $17.00

      8/28/24 7:52:10 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler resumed coverage on Replimune with a new price target

      Piper Sandler resumed coverage of Replimune with a rating of Overweight and set a new price target of $44.00

      4/17/23 7:34:30 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $COYA
    $REPL
    Financials

    Live finance-specific insights

    See more
    • Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

      Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley

      10/28/24 8:00:00 AM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

      Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat

      6/6/24 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

      RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s

      12/5/23 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $COYA
    $REPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

      BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

      4/17/25 7:00:00 AM ET
      $AVIR
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

      Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip

      3/26/24 7:30:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $COYA
    $REPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 4:20:10 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 1:22:38 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 8:35:56 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $COYA
    $REPL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Snyder David S bought $12,934 worth of shares (1,800 units at $7.19), increasing direct ownership by 26% to 8,800 units (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/14/24 6:08:32 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Swaminathan Arun bought $36,797 worth of shares (5,000 units at $7.36), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/13/24 4:05:16 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Grossman Fred bought $19,973 worth of shares (2,710 units at $7.37) (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/12/24 6:03:34 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care